PapamichaelC

[DolPHIN 2 @UoLDolphin2]

Monitoring of DolPHIN2 has been ongoing at IDI this week @IDIMakerere @radboudumc @LSTMnews @livuniITM

[PapamichaelC @c_papamichael]

@UoLDolphin2 a great consortium, wealth of expertise, vast amount of data and great ideas on moving forward during the meeting in Cape Town @LivUni @LSTMnews @IDIMakerere @UCT_news

[DolPHIN 2 @UoLDolphin2]

New York Times coverage of #CROI2019 features DolPHIN-2 study results. Well done team! @nytimes https://t.co/crPe8D6mgN #pmtct #Dolutegravir

[DolPHIN 2 @UoLDolphin2]

Prof Khoo presenting primary outcome analysis at #CROI2019 @UNITAID @livuniITM @LSTMnews @IDIMakerere @uctcider @radboudumc #DTG #pregnancy #pmtc

[DolPHIN 2 @UoLDolphin2]

DolPHIN2 investigators in #Seattle for #CROI2019 looking forward to presenting data on Tuesday @livuniITM @IDIMakerere @uctcider @radboudumc @LSTMnews @UNITAID #DTG #pregnancy

[Kelly Byrne @kellylbyrne17]

First session of #CROI2019. Clinical Trial Design and Analysis. @Helener27 @c_papamichael

[PapamichaelC @c_papamichael]

@justinchiong @stnicsliv @lpoolcouncil Well done Ash :) such amazing news.

[DolPHIN 2 @UoLDolphin2]

Today’s DolPHIN2 training focused on trial safety including use of the causality tool #dolutegravir #pregnancy @IDIMakerere @livuniITM @LSTMnews @UNITAID

[Catriona Waitt @CatrionaWaitt]

@UoLDolphin2 starting a three day training and update at @IDIMakerere

[DolPHIN 2 @UoLDolphin2]

A successful first day of training @IDIMakerere for the DolPHIN2 update @livuninews @livuniITM @LSTMnews @UNITAID #dolutegravir #pregnancy #HIV

[DolPHIN 2 @UoLDolphin2]

The @UoLDolphin2 Liverpool team are looking forward to training in Kampala @livuniITM @LSTMnews @IDIMakerere @UNITAID

[PapamichaelC @c_papamichael]

Well done to the whole team for their hard work. @UoLDolphin2

[DolPHIN 2 @UoLDolphin2]

The Cape Town @UoLDolphin2 team following a successful few days training @uctcider @LSTMnews @radboudumc @livuniITM @UNITAID

[DolPHIN 2 @UoLDolphin2]

Training for DolPHIN2 is underway in Cape Town. Updates on protocol, safety and lots of discussion #dolutegravir #pregnancy @uctcider @LSTMnews @livuniITM @UNITAID

[DolPHIN 2 @UoLDolphin2]

Watch Saye Khoo present D1 study results at #AIDS2018 (from 1:01:00): https://t.co/LkmLcMue5b
69% of late presenting HIV+ pregnant women randomised to DTG had undetectable VL near the time of delivery, compared with 39% of women randomised to EFV-based therapy @WHO @CHAI_health

[Katie McAllister @katiemaymac]

NAM report on DolPHIN-1 study results @UNITAID @KatherineBlumer @CHAI_health @WHOUganda @UCT_news @PEPFAR #dolutegravir #pmtct

[PapamichaelC @c_papamichael]

At the Women in Science symposium @LSTMnews #womeninscience #LSTMwomen

[HIV i-Base @HIViBase]

Breaking news: a safety signal from dolutegravir use at conception. Importantly this is not during pregnancy. Further updates to follow next week... https://t.co/GRIwD43cma

[PapamichaelC @c_papamichael]

Dr Kevin Mortimer chatting about @IMPALA_NIHR over a @pintofscience #Pint18 #LSTM @LSTMnews

[PapamichaelC @c_papamichael]

Ready for the #PintOfScience event in Liverpool #pint18 #LSTM @LivUni @LSTMnews